Goldman Sachs
CNTA

Goldman Sachs’s Centessa Pharmaceuticals CNTA Stock Holding History

Goldman Sachs’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.5M Buy
1,144,560
+365,559
+47% +$9.35M 0.01% 1654
2025
Q4 		$19.5M Buy
779,001
+531,446
+215% +$13.5M ﹤0.01% 2399
2025
Q3 		$6M Sell
247,555
-311,728
-56% -$5.54M ﹤0.01% 3487
2025
Q2 		$7.35M Buy
559,283
+157,519
+39% +$2M ﹤0.01% 3053
2025
Q1 		$5.78M Buy
401,764
+226,198
+129% +$3.7M ﹤0.01% 3209
2024
Q4 		$2.94M Buy
175,566
+162,511
+1,245% +$2.69M ﹤0.01% 3968
2024
Q3 		$209K Buy
+13,055
New +$160K ﹤0.01% 5441
2024
Q2 		– Sell
-55,027
Closed -$622K – 5683
2024
Q1 		$622K Buy
55,027
+30,296
+123% +$287K ﹤0.01% 4634
2023
Q4 		$197K Buy
24,731
+14,081
+132% +$94.4K ﹤0.01% 5160
2023
Q3 		$68.9K Hold
10,650
– – ﹤0.01% 5240
2023
Q2 		$65.9K Sell
10,650
-310
-3% -$1.47K ﹤0.01% 5425
2023
Q1 		$42.2K Sell
10,960
-4,033
-27% -$14.8K ﹤0.01% 5575
2022
Q4 		$46.5K Sell
14,993
-1,536
-9% -$5.69K ﹤0.01% 5607
2022
Q3 		$66K Sell
16,529
-14
-0.1% -$64 ﹤0.01% 5766
2022
Q2 		$81K Buy
+16,543
New +$106K ﹤0.01% 5921

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Goldman Sachs's CNTA Position: Q1 2026 in Review

Goldman Sachs increased its Centessa Pharmaceuticals (CNTA) stake by 47% in Q1 2026, buying an estimated $9.35M and bringing the position to 1,144,560 shares worth $45.5M. The position accounts for 0.01% of the portfolio, ranked #1654.

Goldman Sachs first reported a position in CNTA in Q2 2022 and has held it in 15 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Goldman Sachs held 1,144,560 shares of Centessa Pharmaceuticals worth $45.5M as of Q1 2026.
  • Goldman Sachs bought 365,559 Centessa Pharmaceuticals shares in Q1 2026, an estimated $9.35M.
  • Centessa Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1654 holding.
  • Goldman Sachs first reported a position in Centessa Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.